Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.

Murray KF, Rodrigue JR, González-Peralta RP, Shepherd J, Barton BA, Robuck PR, Schwarz KB; PEDS-C Clinical Research Network.

Clin Trials. 2007;4(6):661-73.

2.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

5.
6.

[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].

Pár A, Tornai I, Szalay F.

Orv Hetil. 2007 May 6;148(18):819-26. Hungarian.

PMID:
17468063
7.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
8.

Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.

Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P; Italian Co-infection Study (ICOS) Group.

Antivir Ther. 2005;10(2):309-17.

PMID:
15865225
9.

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

Pharmacoeconomics. 2004;22(4):257-65.

PMID:
14974875
10.

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.

Cornberg M, Wedemeyer H, Manns MP.

Curr Gastroenterol Rep. 2002 Feb;4(1):23-30. Review.

PMID:
11825538
11.
12.

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.

Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3.

PMID:
18458815
13.

Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan.

Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS.

Intervirology. 2007;50(4):310-5. Epub 2007 Jul 9.

PMID:
17622791
14.

PEG-IFN, RBV dosing during chronic HCV re-treatment.

Highleyman L.

IAPAC Mon. 2007 Feb;13(2):55. No abstract available.

PMID:
17948601
15.

Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.

Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.

Int J Artif Organs. 2008 Apr;31(4):295-302.

PMID:
18432584
16.

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.

Fried MW, Hadziyannis SJ.

Semin Liver Dis. 2004;24 Suppl 2:47-54. Review.

PMID:
15346246
17.

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.

Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

J Gastroenterol Hepatol. 2007 May;22(5):645-52. Erratum in: J Gastroenterol Hepatol. 2007 May;22(5):768.

PMID:
17444850
18.

Treatment of chronic hepatitis C in southern Taiwan.

Chuang WL, Yu ML, Dai CY, Chang WY.

Intervirology. 2006;49(1-2):99-106. Review.

PMID:
16166797
19.

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.

J Viral Hepat. 2003 Jan;10(1):37-42.

PMID:
12558910
20.

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group.

Hepatology. 2005 Nov;42(5):1010-8.

PMID:
16250032

Supplemental Content

Support Center